Topotecan and pegylated liposomal doxorubicin combination as palliative treatment in patients with pretreated advanced malignant pleural mesothelioma

International Journal of Clinical Pharmacology and Therapeutics

Volumn 50, Issue 7, 2012, Pages 490-499

  Trafalis, Dimitrios T ^a   Alifieris, Constantinos ^a   Krikelis, Dimitrios ^a   Tzogkas, Nikolaos ^b   Stathopoulos, George P ^b   Athanassiou, Athanassios E ^c   Sitaras, Nikolaos M ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Errikos Dunant Hospital   (Greece)

^c METAXA CANCER HOSPITAL   (Greece)

Author keywords

Chemotherapy; Malignant pleural mesothelioma; Pegylated liposomal doxorubicin; Pemetrexed pretreated patients; Quality of life; Topotecan

Indexed keywords

CISPLATIN; DOXORUBICIN; HYCAMPTIN; PEMETREXED; TOPOTECAN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HAND FOOT SYNDROME; HUMAN; INFECTION; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PALLIATIVE THERAPY; PLEURA MESOTHELIOMA; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; STOMATITIS; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; FEMALE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PALLIATIVE CARE; PLEURAL NEOPLASMS; POLYETHYLENE GLYCOLS; TOPOTECAN;

EID: 84863643681     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201688     Document Type: Article

References (46)

1. Corson JM. Pathology of diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 1997; 9: 347-355. PubMed
2. Greillier L, Astoul P. Mesothelioma and asbestos-related pleural diseases. Respiration. 2008; 76: 1-15. doi:10.1159/000127577 PubMed
3. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005; 353: 1591-1603. doi:10.1056/NEJMra050152 PubMed
4. Hillerdal G, Sorensen JB, Sundström S, Riska H, Vikström A, Hjerpe A. Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study. J Thorac Oncol. 2008; 3: 1325-1331. doi:10.1097/JTO.0b013e31818b174d PubMed
5. Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998; 16: 145-152. PubMed
6. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998; 113: 723-731. doi:10.1378/chest.113.3.723 PubMed
7. Foroulis CN, Zarogoulidis K, Papakonstantinou C. The role of surgery in the management of malignant pleural mesothelioma. J BUON. 2009; 14: 173-181. PubMed
8. Hillerdal G. Malignant mesothelioma 1982: review of 4710 published cases. Br J Dis Chest. 1983; 77: 321-343. doi:10.1016/0007- 0971(83)90068-2 PubMed
9. Mattson K, Holsti LR, Tammilehto L, Maasilta P, Pyrhönen S, Mäntylä M, Kajanti M, Salminen US, Rautonen J, Kivisaari L. Multimodality treatment programs for malignant pleural mesothelioma using high-dose hemithorax irradiation. Int J Radiat Oncol Biol Phys. 1992; 24: 643-650. doi:10.1016/0360-3016(92)90709-Q PubMed
10. Lindén CJ, Mercke C, Albrechtsson U, Johansson L, Ewers SB. Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: a nonrandomized phase II study. Eur Respir J. 1996; 9: 2565-2572. doi:10.1183/09031936.96.09122565 PubMed
11. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003; 21: 2636-2644. doi:10.1200/ JCO.2003.11.136 PubMed
12. Rusch VW; From the International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma. Chest. 1995; 108: 1122-1128. doi:10.1378/chest.108.4.1122 PubMed
13. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004; 15: 257-260. doi:10.1093/annonc/mdh059 PubMed
14. Anzai H, Frost P, Abbruzzese JL. Synergistic cytotoxicity with combined inhibition of topoisomerase topo I and II [abstract]. Proc Am Assoc Cancer Res. 1992; •••: 33.
15. Jonsson E, Fridborg H, Nygren P, Larsson R. Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients. Eur J Clin Pharmacol. 1998; 54: 509-514. doi:10.1007/ s002280050505 PubMed
16. Whitacre CM, Zborowska E, Gordon NH, Mackay W, Berger NA. Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process. Cancer Res. 1997; 57: 1425-1428. PubMed
17. Oguro M, Seki Y, Okada K, Andoh T. Collateral drug sensitivity induced in CPT-11 (a novel derivative of camptothecin)-resistant cell lines. Biomed Pharmacother. 1990; 44: 209-216. doi:10.1016/0753-3322(90)90026-6 PubMed
18. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem. 1989; 58: 351-375. doi:10.1146/annurev.bi.58.070189.002031 PubMed
19. Eder JP, Chan V, Wong J, Wong YW, Ara G, Northey D, Rizvi N, Teicher BA. Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo. Cancer Chemother Pharmacol. 1998; 42: 327-335. doi:10.1007/s002800050825 PubMed
20. Eckardt JR, Burris HA, Von Hoff DD. Measurement of tumor topoisomerase I and II levels during the sequential administration of Hycamptin and etoposide [abstract]. Proc Am Soc Clin Oncol. 1994; •••: 13.
21. Tolcher AW, O'Shaughnessy JA, Weiss RB, Zujewski J, Myhand RC, Schneider E, Hakim F, Gress R, Goldspiel B, Noone MH, Brewster LR, Gossard MR, Cowan KH. A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies. Clin Cancer Res. 1997; 3: 755-760. PubMed
22. Ghesquières H, Faivre S, Djafari L, Pautier P, Lhommé C, Lozahic S, Djazouli K, Armand JP, Raymond E. Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignancies. Invest New Drugs. 2006; 24: 413-421. doi:10.1007/s10637-006-7520-2 PubMed
23. Ryan CW, Fleming GF, Janisch L, Ratain MJ. A phase I study of liposomal doxorubicin (Doxil) with topotecan. Am J Clin Oncol. 2000; 23: 297-300. doi:10.1097/00000421-200006000-00019 PubMed
24. Seiden MV, Ng SW, Supko JG, Ryan DP, Clark JW, Lynch T, Huang KC, Kwiatkowski D, Skarin A, Eder JP Jr. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors. Clin Cancer Res. 2002; 8: 691-697. PubMed
25. Penson RT, Seiden MV, Goodman A, Fuller AF Jr, Berkowitz RS, Matulonis UA, Krasner C, Lee H, Atkinson T, Campos SM; Gynecologic Oncology Research Program at Dana Farber/Partners CancerCare. Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies. Gynecol Oncol. 2004; 93: 702-707. doi:10.1016/j.ygyno.2004.02.028 PubMed
26. Garcia AA, Roman L, Muderspach L, O'meara A, Facio G, Edwards S, Burnett A. Phase I clinical trial of topotecan and pegylated liposomal doxorubicin. Cancer Invest. 2005; 23: 665-670. doi:10.1080/07357900500359877 PubMed
27. Mirchandani D, Hochster H, Hamilton A, Liebes L, Yee H, Curtin JP, Lee S, Sorich J, Dellenbaugh C, Muggia FM. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer. Clin Cancer Res. 2005; 11: 5912-5919. doi:10.1158/1078-0432.CCR-04-1240 PubMed
28. Verhaar-Langereis M, Karakus A, van Eijkeren M, Voest E, Witteveen E. Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer. Int J Gynecol Cancer. 2006; 16: 65-70. doi:10.1111/j.1525-1438.2006.00298.x PubMed
29. Rose PG, Smrekar M, Haba P, Fusco N, Rodriguez M. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum- resistant ovarian and peritoneal cancer. Am J Clin Oncol. 2008; 31: 476-480. doi:10.1097/ COC.0b013e31816a6221 PubMed
30. Colbert N, Vannetzel JM, Izrael V, Schlienger M, Milleron B, Blanchon F, Herman D, Akoun G, Roland J, Chatelet F, Laugier A. A prospective study of detorubicin in malignant mesothelioma. Cancer. 1985; 56: 2170-2174. doi:10.1002/1097- 0142(19851101)56:9〈2170::AIDCNCR2820560905〉3.0.CO;2- L PubMed
31. Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008; 26: 1698-1704. doi:10.1200/ JCO.2006.09.9887 PubMed
32. Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, Nackaerts K, Lianes P, Vogelzang NJ. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cispla tin alone in malignant pleural mesothelioma. Ann Oncol. 2005; 16: 923-927. doi:10.1093/annonc/ mdi187 PubMed
33. Stebbing J, Powles T, McPherson K, Shamash J, Wells P, Sheaff MT, Slater S, Rudd RM, Fennell D, Steele JP. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer. 2009; 63: 94-97. doi:10.1016/j.lungcan.2008.04.001 PubMed
34. Baas P, van Meerbeeck J, Groen H, Schouwink H, Burgers S, Daamen S, Giaccone G. Caelyx in malignant mesothelioma: a phase II EORTC study. Ann Oncol. 2000; 11: 697-700. doi:10.1023/A:1008346925273 PubMed
35. Oh Y, Perez-Soler R, Fossella FV, Glisson BS, Kurie J, Walsh GL, Truong M, Shin DM. Phase II study of intravenous Doxil in malignant pleural mesothelioma. Invest New Drugs. 2000; 18: 243-245. doi:10.1023/A:1006421706540 PubMed
36. Skubitz KM. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in mesothelioma. Cancer Invest. 2002; 20: 693-699. doi:10.1081/CNV-120003538 PubMed
37. Maksymiuk AW, Marschke RF Jr, Tazelaar HD, Grill J, Nair S, Marks RS, Brooks BJ, Mailliard JA, Burton GM, Jett JR. Phase II trial of topotecan for the treatment of mesothelioma. Am J Clin Oncol. 1998; 21: 610-613. doi:10.1097/00000421-199812000-00017 PubMed
38. Razak AR, Chatten KJ, Hughes AN. Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option. Lung Cancer. 2008; 60: 294-297. doi:10.1016/j.lungcan.2007.08.031 PubMed
39. Serke M and Bauer T. Pemetrexed in second-line therapy in patients with malignant pleural mesothelioma (abstract). ASCO MEETING ABSTRACTS 2007;18S.
40. Ceresoli GL, Zucali PA, De Vincenzo F, Gianoncelli L, Simonelli M, Lorenzi E, Ripa C, Giordano L, Santoro A. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer. 2011; 72: 73-77. doi:10.1016/j.lungcan.2010.12.004 PubMed
41. Xanthopoulos A, Bauer TT, Blum TG, Kollmeier J, Schönfeld N, Serke M. Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study. J Occup Med Toxicol. 2008; 3: 34. doi:10.1186/1745-6673-3-34 PubMed
42. Zucali PA, Ceresoli GL, Garassino I, De Vincenzo F, Cavina R, Campagnoli E, Cappuzzo F, Salamina S, Soto Parra HJ, Santoro A. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer. 2008; 112: 1555-1561. doi:10.1002/cncr.23337 PubMed
43. Jackman DM, Kindler HL, Yeap BY, Fidias P, Salgia R, Lucca J, Morse LK, Ostler PA, Johnson BE, Jänne PA. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 2008; 113: 808-814. doi:10.1002/cncr.23617 PubMed
44. Cortese JF, Gowda AL, Wali A, Eliason JF, Pass HI, Everson RB. Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. Int J Cancer. 2006; 118: 521-522. doi:10.1002/ijc.21271 PubMed
45. Ramalingam SS, Belani CP, Ruel C, Frankel P, Gitlitz B, Koczywas M, Espinoza-Delgado I, Gandara D. Frankel P, Gitlitz B, Koczywas M, Espinoza-Delgado I and Gandara D. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol. 2006; 4: 97-101. doi:10.1097/ JTO.0b013e318191520c
46. Gregorc V, Zucali PA, Santoro A, Ceresoli GL, Citterio G, De Pas TM, Zilembo N, De Vincenzo F, Simonelli M, Rossoni G, Spreafico A, Grazia Viganò M, Fontana F, De Braud FG, Bajetta E, Caligaris-Cappio F, Bruzzi P, Lambiase A, Bordignon C. Phase II study of asparagine-glycinearginine- human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J Clin Oncol. 2010; 28: 2604-2611. doi:10.1200/JCO.2009.27.3649 PubMed